About Melin Khandekar, MD, PhD

Dr. Khandekar graduated with distinction and departmental honors from Stanford University with a B.S. in biological sciences.  He enrolled in the Medical Scientist Training Program at Northwestern University and obtained his M.D. from the Feinberg School of Medicine at Northwestern University as well as a Ph.D. in Cell and Developmental Biology at the University of Michigan. He completed an internship in Internal Medicine at Brigham and Women's Hospital, followed by residency training in the Harvard Radiation Oncology Program.  He was a Holman Research Fellow, and has done postdoctoral research with Dr. Bruce Spiegelman at the Dana Farber Cancer Institute.  Dr. Khandekar has a busy clinical practice focusing on the care of patient with thoracic cancers of various types as well as brain metastases from lung cancer.   He also does laboratory research focusing on the effects of systemic physiology on cancer and the tumor microenvironment, and is interested in repurposing drugs developed in metabolic disease in cancer therapy. His goal is to personalize lung cancer care, combining tumor genomics, patient physiology, precision radiation techniques and systemic therapies to maximize the chances of lung cancer cure.

Departments, Centers, & Programs:

Clinical Interests:



Clark Center for Radiation Oncology
100 Blossom Street
Boston, MA 02114-2606
Phone: 617-726-5184

Medical Education

  • MD, Northwestern University, Feinberg School of Medicine
  • PhD, University of Michigan Medical School
  • Residency, Brigham and Women's Hospital
  • Residency, MGH/Harvard Radiation Oncology Program

American Board Certifications

  • Radiation Oncology, American Board of Radiology

Accepted Insurance Plans

Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.


Dr. Khandekar's clinical research activities focus on the application of stereotactic body radiation therapy (SBRT) in patients with early-stage and metastatic NSCLC as well as lung metastases and optimizing the role of radiation therapy in the management of brain metastases from NSCLC

Dr. Khandekar's lab research aims to understand the effects of alterations of the systemic physiology of the patient, including comorbidities such as hypertension, diabetes and obesity on the tumor and tumor microenviroment.  He hopes to repurpose drugs developed to treat these conditions, including anti-diabetic agents that modulate PPAR-gamma as well as anti-hypertensives that block renin-angiotensin signaling to identify optimal combinations of systemic therapy and radiation that will improve the chance to cure lung cancer and other thoracic cancers.